Clene (Nasdaq: CLNN) will present a corporate update at the Emerging Growth Conference on February 25, 2026 at 1:45 p.m. ET. The presentation will be virtual and available live via webcast and later as a replay on the conference portal and YouTube.
The webcast can be accessed through Clene's Events page or by registering at the conference webcast link; a replay will be posted after the event.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CLNN
+4.65%
2 alerts
+4.65%Session close to close
+5.4%Peak Tracked
$59.48MMarket Cap
0.6xRel. Volume
In the Feb 19 session, CLNN gained 4.65%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +5.4% during that session.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
This announcement schedules a virtual corporate update on February 25, 2026 at 1:45 p.m. ET at the E...
Analysis
This announcement schedules a virtual corporate update on February 25, 2026 at 1:45 p.m. ET at the Emerging Growth Conference, continuing Clene’s pattern of using this forum for investor communication. Against a backdrop of recent ALS biomarker data, a registered direct offering, and an active S-3 resale shelf with going-concern disclosure, investors may focus less on the event itself and more on forthcoming clinical, regulatory, and financing milestones that could reshape the risk profile.
Key Figures
Current price:$4.5224h price change:7.11%52-week high:$13.50+5 more
8 metrics
Current price$4.52Pre-news trading level for CLNN
24h price change7.11%Move in prior 24 hours before this news
52-week high$13.50CLNN 52-week high price
52-week low$2.2801CLNN 52-week low price
Today’s volume28,208 sharesVersus 20-day average volume of 79,283 shares
200-day MA$5.64CLNN trading below this moving average
Statistically significant ALS biomarker results for CNM-Au8 supporting accelerated approval.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows frequent divergence: positive clinical and financing news often saw negative reactions, while neutral conference updates produced mixed but generally aligned moves.
Recent Company History
Over the last few months, CLNN has issued multiple clinically focused and financing updates alongside recurring Emerging Growth Conference appearances. Positive ALS biomarker and survival data and accelerated-approval discussions (e.g., Dec 3, 2025 and Jan 12, 2026) were followed by notable share price drops, while a registered direct offering of about $28M on Jan 9, 2026 saw a positive reaction. Neutral conference presentations on Dec 10, 2025 and Jan 21, 2026 produced modest, mixed moves. Today’s new conference appearance fits this pattern of ongoing corporate communication rather than a fresh clinical or financing catalyst.
Key Terms
mitochondrial, neuronal, neurodegenerative diseases, amyotrophic lateral sclerosis (ALS), +2 more
6 terms
mitochondrialmedical
"focused on improving mitochondrial health and protecting neuronal function"
Relating to mitochondria, the tiny structures inside cells that act like power plants to produce the energy cells need and help control cell survival. For investors this matters because problems with mitochondrial function are linked to certain diseases and are a focus for drugs, diagnostics and safety testing, so claims about “mitochondrial” effects can signal potential market opportunities or risks for healthcare-related companies.
neuronalmedical
"improving mitochondrial health and protecting neuronal function to treat"
Relating to neurons, the specialized cells that carry signals in the brain and nervous system; think of neurons as the body's electrical wiring that sends messages between parts of the body and the brain. For investors, the term flags that a product, trial or risk involves the nervous system, which can mean large potential markets, complex safety and regulatory hurdles, and longer development timelines compared with non-neurological treatments.
neurodegenerative diseasesmedical
"to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS)"
Neurodegenerative diseases are conditions where brain or nerve cells progressively lose function and die, causing symptoms like memory loss, movement problems, or cognitive decline — think of the brain’s wiring slowly wearing out. Investors care because these illnesses create sustained demand for treatments, diagnostics, and long-term care, drive regulatory decisions and clinical-trial milestones that move stock prices, and concentrate both high development risk and the potential for large financial returns if effective therapies are approved.
amyotrophic lateral sclerosis (ALS)medical
"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple"
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages nerve cells responsible for controlling voluntary muscles, leading to muscle weakness, loss of movement, and eventually paralysis. It matters to investors because health-related research, treatments, and biotech companies working on ALS can influence stock markets and create opportunities or risks within the healthcare sector.
multiple sclerosis (MS)medical
"including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"
Multiple sclerosis (MS) is a chronic neurological disease in which the immune system damages the insulating sheath around nerve fibers in the brain and spinal cord, interrupting electrical signals and causing symptoms like weakness, numbness, vision problems, and fatigue. Investors pay attention because MS drives long-term demand for therapies, clinical trial outcomes and regulatory approvals can sharply change a drugmaker’s revenue prospects, and advances or setbacks in treatment options affect long-term healthcare costs and company valuations.
webcasttechnical
"A webcast of the presentation will be available on the “Events” section"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Virtual Presentation Details Date: February 25, 2026 Time of Presentation: 1:45 p.m. ET Format: Corporate update
About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Clene Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
When will Clene (CLNN) present at the Emerging Growth Conference in February 2026?
Clene will present on February 25, 2026 at 1:45 p.m. ET, delivering a corporate update. According to the company, the session is virtual and accessible via webcast with a replay available after the live presentation.
How can investors watch Clene's (CLNN) Emerging Growth Conference presentation on February 25, 2026?
Investors can view the live webcast by registering through the conference link or via Clene's Events page. According to the company, a replay will also be posted on the conference portal and the Emerging Growth YouTube channel.
What will Clene (CLNN) cover during its February 25, 2026 Emerging Growth Conference presentation?
Clene will deliver a corporate update focused on recent developments and strategy. According to the company, the format is a management presentation intended to communicate company progress to investors and analysts.
Will a replay of Clene's (CLNN) February 25, 2026 presentation be available after the event?
Yes, a replay will be available through the conference portal and the Emerging Growth YouTube channel after the event. According to the company, the replay will remain accessible for viewers who cannot attend live.
Where can analysts find the webcast registration link for Clene's (CLNN) February 25, 2026 presentation?
Analysts can register using the conference webcast registration URL provided by the event organizer. According to the company, the same registration link is listed on Clene's Events webpage for convenience.
